Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Levomilnacipran

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 601Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zydus Lifesciences’ arm gets USFDA approval for anti-depression capsules
    Zydus Lifesciences’ arm gets USFDA approval for anti-depression capsules

    17 Jan 2023

    // BQPRIME

    https://www.bqprime.com/markets/zydus-lifesciences-arm-gets-usfda-nod-to-sell-depression-treatment-drug

    BQPRIME
    17 Jan 2023
    Share Share
    Zydus' Generic Levomilnacipran Receives Approval in the U.S.
    Zydus' Generic Levomilnacipran Receives Approval in the U.S.

    12 Jan 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210857

    FDA
    12 Jan 2023
    Share Share
    Zydus' Generic Levomilnacipran Receives Approval in the U.S.
    Zydus' Generic Levomilnacipran Receives Approval in the U.S.

    12 Jan 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210857

    FDA
    12 Jan 2023
    Share Share
    Prinston's Generic Levomilnacipran Receives Approval in the U.S.
    Prinston's Generic Levomilnacipran Receives Approval in the U.S.

    17 Aug 2022

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210771

    FDA
    17 Aug 2022
    Share Share
    MSN Lab's Generic Levomilnacipran Receives Tentative Approval In US
    MSN Lab's Generic Levomilnacipran Receives Tentative Approval In US

    04 Jun 2020

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210805

    FDA
    04 Jun 2020
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Fetzima (Levomilnacipran) Capsules
    FDA Confirms Paragraph IV Patent Challenge of Fetzima (Levomilnacipran) Capsules

    27 Sep 2017

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-fetzima-levomilnacipran-capsules-1506579255.pdf

    FDA
    27 Sep 2017
    Share Share